Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 4
1(100.0%)
1Total
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05614050Recruiting

The Prognosis of Patients After PCI：a Multi-center Study in China

Role: collaborator

NCT06236022Phase 4Recruiting

The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus

Role: collaborator

NCT05206890Recruiting

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Role: collaborator

All 3 trials loaded